Investigational Products

[F-18]-DCFPyL Injection

[F-18]-DCFPyL Injection is a novel, urea-based, small molecule imaging biomarker that targets prostate-specific membrane antigen (PSMA). PSMA is overexpressed in prostate cancer, particularly in poorly differentiated, hormone-independent and metastatic disease; this makes PSMA a useful target in patients with more aggressive forms of prostate cancer.

In combination with positron emission tomography (PET), [F-18]-DCFPyL has potential as a tool to guide treatment planning, predict treatment response and inform about the prognosis in patients with primary and metastatic prostate cancer.

References

Maurer T, Eiber M, Schwaiger M et al. Current use of PSMA-PET in prostate cancer management. Nature Reviews Urology. 2016; 13(4): 226-235.

http://www.ncbi.nlm.nih.gov/pubmed/25552670

Szabo Z, Mena E, Rowe SP et al. Initial Evaluation of ¹⁸F-DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Mol Imaging Biol. 2015; 17(4): 565-574.

http://www.ncbi.nlm.nih.gov/pubmed/25896814

Dietlein M, Kobe C, Kuhnert G et al. Comparison of ¹⁸F-DCFPyL and ⁶⁸Ga-PSMA-HBED-CC for PSMA PET Imaging in Patients with Relapsed Prostate Cancer. Mol Imaging Biol. 2015; 17(4): 575-584.

http://www.ncbi.nlm.nih.gov/pubmed/26013479

These references are provided for informational purposes only and do not represent an endorsement for any particular clinical use.

Investigational Use Only

The safety and efficacy of [F-18]-DCFPyL Injection have not been fully established and it has not been approved by Health Canada as a commercial product for medicinal use. It is an investigational drug product and can only be used under a Clinical Trial Application (CTA). Please contact the UHNRC if you require further information.